证券代码：000566 证券简称：海南海药 公告编号：2025-067 海南海药股份有限公司 关于持股 5%以上股东部分股份被司法拍卖的结果公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 1 股份被司法拍卖的提示性公告》（公告编号：2025-059）和《关于持股 5%以上 股东部分股份被司法拍卖的进展公告》（公告编号：2025-060，2025-061） 二、本次拍卖的竞买结果情况 根据 2025 年 11 月 2 日京东网司法拍卖网络平台公示的《成交确认书》，本 次拍卖成交总价格为 33,650,726.39 元，竞买人为张宇，本次拍卖成交共计 6,208,900 股，占公司股份总数的 0.48%。具体成交情况如下： 特别提示 1、本次司法拍卖标的为公司持股 5%以上股东深圳市南方同正投资有限公司 （以下简称"南方同正"）所持海南海药股份有限公司（以下简称"公司"或"海 南海药"）已质押的 123,825,900 股股票，占其所持公司全部股份的 92.86%， 占公司总股本的 9.54%。 2、根据京东司法拍卖平台页面显示的拍卖结果，截至本公告披露日， ...

Policy Developments - The National Health Commission and five other departments launched a one-year special campaign against illegal ambulances, targeting both registered "ambulance" vehicles and unregistered "black ambulances" [2] - The campaign includes comprehensive inspections, management principles, and encourages social participation in medical transport services [2][3] Drug and Medical Device Approvals - Aied Bio received a medical device registration certificate for its gene mutation detection kit, which is now approved in China, Japan, and Europe, aiding non-small cell lung cancer patients [4] - Hainan Haiyao's subsidiary obtained a drug registration certificate for Fumaric Acid Vonoprazan Tablets, the first P-CAB for reflux esophagitis in China [5] Capital Market Activities - China National Pharmaceutical Modern signed a drug listing license transfer contract for Lactulose Oral Solution, with a total transfer fee of 5.86 million yuan, projected to generate 2.069 billion yuan in sales in 2024 [6] - Jiangsu Hengrui Medicine and Neurocrine Biosciences entered a collaboration for developing NLRP3 inhibitors, with a potential total value of $881.5 million [7][8] Industry Events - The 2025 medical insurance negotiation concluded, with results expected to be announced in early December [9] - The only approved stem cell drug in China, Aimi Maito Sai Injection, is included in the "Beijing Universal Health Insurance" with a maximum reimbursement of 65% [10] Regulatory Issues - The executive director of CSPC Pharmaceutical Group was fined 5 million yuan for insider trading related to a merger announcement [11]

Group 1 - China Mobile's controlling shareholder, China Mobile Group, plans to transfer 41.98 million shares (0.19% of total shares) to China National Petroleum Corporation [1] - Strong瑞 Technology intends to invest 70 million yuan to acquire 35% equity in aluminum cooling technology company, which supplies components for NVIDIA AI servers [2] - Pingtan Development's stock price has increased over 100% in the last eight trading days, indicating significant abnormal trading behavior [3] Group 2 - Hezhong China warns of irrational speculation risk as its stock price has surged 61.23% over five consecutive trading days, significantly deviating from its fundamentals [4] - TCL Technology's participation in the restructuring plan of Suning Group has not been approved by creditors, leading to uncertainties in the restructuring process [5] - Huitian New Materials has signed a strategic cooperation agreement with Taiblue New Energy to collaborate in solid-state batteries and key materials [6] Group 3 - Han Jian He Shan has signed a procurement contract worth 207 million yuan with China Nuclear Industry Huaxing Construction, accounting for 26.29% of its audited revenue for 2024 [7] - Actual controller of Baihehua, Chen Lirong, mistakenly reduced his holdings by 160,000 shares but has since repurchased the same amount [8][9] - Yaxing Chemical is planning to acquire control of Tianyi Chemical through a combination of share issuance and cash payment, leading to a stock suspension [10] Group 4 - Shenghui Integration's shareholder, Suzhou Shengzhan, has terminated its plan to reduce holdings of up to 620,000 shares, having already reduced 565,500 shares [11] - North Bay Port reported a 22.73% year-on-year increase in cargo throughput in October [12] - Jiangling Motors experienced an 8.06% year-on-year increase in automobile sales in October [12]

Core Viewpoint - Hainan Haiyao's subsidiary has received approval for a new chemical drug, indicating potential growth in its pharmaceutical portfolio and market presence [1] Group 1: Company Developments - Hainan Haiyao's wholly-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., has obtained the Drug Registration Certificate for "Fumaric Acid Vonoprazan Tablets" from the National Medical Products Administration [1] - The registered indication for the drug is gastroesophageal reflux disease, which can be used in conjunction with appropriate antibiotics to eradicate Helicobacter pylori [1]

Core Viewpoint - Hainan Haiyao's subsidiary has received approval for a new chemical drug, indicating a positive development in its product pipeline and potential market expansion [1] Group 1 - The company announced that its wholly-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., has obtained the Drug Registration Certificate for "Fumaric Acid Vonoprazan Tablets" from the National Medical Products Administration [1] - The registered indication for the drug is gastroesophageal reflux disease, which is a significant condition that affects many patients [1] - The drug is intended to be used in conjunction with appropriate antibiotics to eradicate Helicobacter pylori, a common bacterial infection linked to various gastrointestinal diseases [1]

证券代码：000566 证券简称：海南海药 公告编号：2025-066 海南海药股份有限公司 关于子公司获得富马酸伏诺拉生片药品注册批件的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）全资子公司海口市制药厂有限 公司近日获得国家药品监督管理局核准签发的化学药品"富马酸伏诺拉生片"的 《药品注册证书》。现将相关情况公告如下： 一、产品基本情况 1、药品名称：富马酸伏诺拉生片 剂型：片剂 规格：10mg、20mg 受理号：CYHS2401390、CYHS2401391 注册分类：化学药品 4 类 适应症：反流性食管炎。与适当的抗生素联用以根除幽门螺杆菌。 药品上市许可持有人：海口市制药厂有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 2、药品的其他相关情况 富马酸伏诺拉生是一款钾离子竞争性酸阻滞剂（P-CAB），与传统的质子泵 抑制剂（PPI）相比，伏诺拉生具有更快的起效速度、更长的作用时间和更强的 抑制胃酸分泌效果。目前富马酸伏诺拉生 ...

Core Viewpoint - Hainan Haiyao's stock price has shown a significant increase this year, with a 25.47% rise, despite a recent decline over the past 60 days [1][2] Group 1: Stock Performance - As of October 31, Hainan Haiyao's stock price reached 6.01 CNY per share, with a market capitalization of 7.797 billion CNY [1] - The stock has experienced a 5.07% increase over the last five trading days and a 9.07% increase over the last 20 trading days, while it has decreased by 6.39% over the last 60 days [1] - The company has appeared on the stock market's "龙虎榜" three times this year, with the latest occurrence on June 3 [1] Group 2: Financial Performance - For the period from January to September 2025, Hainan Haiyao reported a revenue of 640 million CNY, representing a year-on-year decrease of 20.51%, while the net profit attributable to shareholders was -242 million CNY, showing a year-on-year increase of 17.91% [2] - The company has cumulatively distributed 466 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3] Group 3: Shareholder Information - As of October 20, the number of shareholders for Hainan Haiyao increased by 4.70% to 77,500, while the average number of circulating shares per person decreased by 4.49% to 15,040 shares [2] - As of September 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 6.6464 million shares, a decrease of 1.1481 million shares from the previous period [3]

Group 1 - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for any false records or misleading statements [2][10][29] - The third-quarter financial report has not been audited [9][10] - The company has received cash of 33.19 million yuan and has 101 sets of commercial housing registered under its name as part of debt compensation [6][7] Group 2 - The company has initiated legal proceedings against Southern Tongzheng and Hainan Haiyao Real Estate for failure to repay debts, with a court ruling requiring payment of approximately 311.17 million yuan and 200.45 million yuan in principal and penalties [7][8] - The company will hold its fifth extraordinary general meeting on November 18, 2025, to discuss various proposals, including amendments to the articles of association and the establishment of a new governance structure [11][35][36] - The board of directors has approved the adjustment of the special committee members to enhance governance efficiency [30][31][32]

证券代码：000566 证券简称：海南海药 公告编号：2025-064 海南海药股份有限公司 关于修订<公司章程>的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（下称"公司"）根据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司章程指引》等有关法律法规、深圳证券交易所 的相关规定，结合公司实际情况和经营发展需要，公司拟对《公司章程》部分条 款进行修订。本次修订后的《公司章程》需经公司股东大会审议通过后方可生效。 修改后的《公司章程》经股东大会审议通过后，公司将不再设监事会，原监 事会将停止履职，监事自动解任,《监事会议事规则》相应废止，公司各项制度 中涉及监事会、监事的规定不再适用。公司对各位监事在任职期间做出的贡献表 示诚挚的感谢。 在本次修订过程中，除对比表所示修订内容外，公司另根据《公司法》《上 市公司章程指引（2025 年修订）》等法律法规和规范性文件，将《公司章程》全 文的"股东大会"表述修改为"股东会"；同时统一表述，将阿拉伯数字统一为 中文，将"或"统一为"或者"。如因增加、删除、排列某些章节、条款导致章 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-065 海南海药股份有限公司 关于召开 2025 年第五次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2025 年第五次临时股东大会 2、股东大会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法 律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 7、出席对象： （1）在股权登记日持有公司股份的普通股股东或其代理人。 于 2025 年 11 月 11 日下午收市时，在中国证券登记结算有限责任公司深圳分公司登 记在册的全体普通股股东均有权出席股东大会。股东可以书面委托代理人出席会议和参加 表决（该股东代理人不必是公司的股东）。 （2）公司董事、监事和高级管理人员。 （3）公司聘请的律师。 （4）根据相关法规应当出席股东大会的其他人员。 4、会议时间： （1）现场会议时间：2025 年 11 月 1 ...